Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
for Renal Cell Carcinoma (RCC)
44 locations incl. Phoenix
Sponsor: Exelixis
Sex: All·Age: 18+
Code: NCT05176483·Phase 1·Recruiting·Listed Jan 2022
Exelixis Clinical
Clinical research site in Irving, Texas · 4425 W AIRPORT FWY STE 149, IRVING, TX 75062-5850 · (972) 765-2606
Part of Exelixis Clinical
As of July 2026, 1 paid clinical trial is recruiting at Exelixis Clinical in Irving, Texas. Active studies at this site cover conditions such as Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Urothelial Carcinoma (UC). Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Recruiting clinical trials at Exelixis Clinical (1)
More research sites in Irving
- NEXT Dallas (18 trials)
- NEXT Oncology (10 trials)
- NEXT Oncology Dallas (9 trials)
- US Oncology Investigational Product Center (IPC) (8 trials)
- US Oncology Investigational Products Center (IPC) (8 trials)
- NEXT Oncology - Dallas (7 trials)
- US Oncology Investigational Products Center (4 trials)
- Texas Center for Proton Therapy (3 trials)
- US Oncology Research Investigational Products Center (3 trials)
- NEXT Dallas - Oncology Department (2 trials)